Different β -Blockers in STEMI and Primary PCI

Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04221919

Enrollment

1200

Registered

2020-01-09

Start date

2020-01-31

Completion date

2025-01-31

Last updated

2020-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary PCI

Brief summary

Carvedilol, target dose: 50 mg daily; Bisoprolol, target dose: 10 mg daily; Metoprolol tartrate, target dose: 150 mg daily; Metroprolol succinate, target dose: 200 mg daily

Detailed description

The investigators will investigate the efficacy and safety of different β -blockers, as well as heart rate variability, in STEMI patients undergoing primary PCI.

Interventions

DRUGβ -Blockers

Target doses of carvedilol, bisoprolol, metoprolol tartrate, or metroprolol succinate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Admitted for primary PCI for STEMI involving the LAD within 12 hours of onset of symptoms. STEMI will be defined as typical ECG changes (ST segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes; * Age ≥18 years; * Informed consent from patient or next of kin.

Exclusion criteria

* Nonischaemic Cardiomyopathy; * Cardiac surgery planed in the 6 months; * Mechanical complication of STEMI (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation); * Renal or hepatic failure; * Malignancy, HIV, or central nervous system disorder; * Cardiopulmonary resuscitation \>15 min and compromised level of consciousness; * Cardiogenic shock; * Current participation in any research study involving investigational drugs or devices; * No written consensus; * Previous myocardial infarction.

Design outcomes

Primary

Measure	Time frame	Description
Change in LVEDV from baseline	1 to 5 years	The primary outcome of this study will be the change from baseline in left ventricular end diastolic volume (LVEDV) post-PCI.
Major adverse cardiovascular events (MACE)	1 to 5 years	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026